Therefore, the improvement of executive functions (atypical antipsychotic-resistant cognitive domains) in treatment-resistant schizophrenia by a relatively low dose of lurasidone suggests that 5-HT7R antagonism plays an important role in the cognition-promoting effects of lurasidone, rather than 5-HT2A antagonism or 5-HT1AR partial agonism. This evidence concerns the gene HTR2A and schizophrenia.